PENMENVY Availability Through the Vaccines for Children (VFC) Program

On April 16, 2025, the Advisory Committee on Immunization Practices (ACIP) recommended that MenACWY-CRM/MenB-4C may be administered to persons aged ≥10 years when both a quadrivalent meningococcal conjugate vaccine (MenACWY) and meningococcal B vaccine (MenB) are indicated at the same visit. These recommendations can be referenced in the VFC Resolution: Advisory Committee on Immunization Practices Vaccines for Children Program Vaccines to Prevent Meningococcal Disease. 

Meningococcal disease is a life-threatening invasive infection caused by Neisseria meningitidis. The pentavalent meningococcal vaccine MenACWY-CRM/MenB-4C (PENMENVY, GlaxoSmithKline) protects against five 
N. meningitidis serogroups, A, B, C, W, and Y, and is licensed by the Food and Drug Administration (FDA) for use among persons aged 10 through 25 years. PENMENVY is the second pentavalent meningococcal vaccine approved for protection against these five serogroups. The first was PenbrayaTM (Pfizer), which ACIP recommended in 2023. 

Providers should be aware that MenB vaccines from different manufacturers are not interchangeable. If a patient receives a pentavalent meningococcal vaccine, subsequent doses of MenB vaccine should be from the same manufacturer.

Availability Through the VFC Program
PENMENVY will be available for order through the ImpactSIIS Vaccine Ordering Management System (VOMS) beginning Wednesday, October 1, 2025. Vaccine shipments will be facilitated by McKesson, the federal vaccine distributor, based on product availability. PENMENVY ordered through the VFC Program is to be administered to appropriate individuals who meet the ACIP recommendation eligibility and VFC eligibility criteria1 through 18 years of age. 

PENMENVY Product Information:

  • PENMENVY    
  • VOMS Order Set: VFC- Refrigerated    
  • Presentation: Single dose vials    
  • Minimum Order Quantity: 10

Storage and Handling 

  • Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton. Do not freeze.
  • The prefilled syringe’s vial stopper, tip cap, and plunger are not made with natural rubber latex.
  • PENMENVY is supplied as one vial of lyophilized MenACWY Component (powder) and one prefilled syringe of MenB Component (liquid) which must be combined before administration. 
  • Needles are NOT supplied.
  • To prepare PENMENVY, reconstitute the lyophilized MenACWY component with the MenB component. 
  • After reconstitution, administer PENMENVY immediately. 

Planning Considerations

  • A VFC provider who serves patients who meet the vaccine recommendation criteria above will be able to order and administer PENMENVY to VFC-eligible patients.
  • PENMENVY can be ordered in increments of 10 doses.
  • VOMS is available for providers to place orders 24 hours a day, seven days a week. 
  • If PENMENVY is administered as the first dose in a MenB series, subsequent MenB doses must be completed with GSK’s Bexsero® (to ensure manufacturer consistency).

Please contact the Immunization Program at 1-800-282-0546 if you have any questions.

Footnotes:

  1. VFC Vaccine Eligibility

Children through age 18 years who meet at least one of the following four criteria are considered federally vaccine-eligible and therefore eligible for vaccine through the VFC program:

  • Medicaid eligible: A child who has health insurance covered by a state Medicaid program. 
  • Uninsured: A child who has no health insurance coverage. 
  • American Indian or Alaska Native: As defined by the Indian Health Care Improvement Act (25 U.S.C. 1603). 
  • Underinsured: Underinsured children are eligible to receive VFC vaccine only through a federally qualified health center (FQHC), rural health clinic (RHC), or a public health department that receives deputized authority from a FQHC or RHC. 

For the purposes of VFC, underinsured includes a child through 18 years of age is considered underinsured if the child has health insurance but the policy:

  • Does not cover any ACIP-recommended vaccines. (Underinsured for all vaccines).
  • Does not cover certain ACIP-recommended vaccines. (Underinsured for non-covered vaccines only).
  • Does not provide first dollar coverage (which includes co-pays, co-insurance, or deductibles) for ACIP-recommended vaccines. (Underinsured for vaccines until the child has health insurance with first-dollar coverage for vaccines.)
  • Covers ACIP-recommended vaccines but has a fixed dollar limit (or cap) for payment. (Underinsured once the policy reaches the fixed dollar cap).